TrialSchizophrenia bulletin2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms.

Dragana Bugarski-Kirola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.